🔬 Fresh insights from #AACR2025 are fuelling our mission at BeLiver. Our CSO, Frederic Saltel, is back from Chicago, where he exchanged with global cancer research leaders. This is crucial for our innovative predictive tests.

✨ The energy and discussions at AACR, especially with leading clinicians, were incredibly encouraging. This confirms the growing need for smarter, personalized approaches to tackle advanced Hepatocellular Carcinoma (hashtag#HCC). Every conversation strengthens our determination to refine our technology and improve patient outcomes.

🚀 For a growing company like BeLiver, these scientific exchanges are invaluable. They validate our unique proteomic approach and help us build a network of collaborators, advisors, and future talents who share our passion for making a real difference. This U.S. engagement marks a key step in our international growth.

🔗 Want to learn more about how BeLiver is shaping the future of HCC care? Let's connect! We're eager to discuss our science and vision.

‍